| Primary |
| Drug Use For Unknown Indication |
46.2% |
| Urinary Tract Infection |
6.4% |
| Product Used For Unknown Indication |
5.4% |
| Infection |
4.7% |
| Lung Disorder |
4.5% |
| Prophylaxis |
3.7% |
| Prostatitis |
3.2% |
| Sepsis |
3.2% |
| Pyrexia |
3.0% |
| Pyelonephritis |
2.8% |
| Bronchitis |
2.3% |
| Depression |
2.0% |
| Hypertension |
1.8% |
| Intervertebral Discitis |
1.8% |
| Atrial Fibrillation |
1.7% |
| Staphylococcal Infection |
1.7% |
| Endocarditis |
1.5% |
| Pain |
1.5% |
| Intentional Overdose |
1.3% |
| Multiple Myeloma |
1.3% |
|
| Tendonitis |
9.1% |
| Thrombocytopenia |
9.1% |
| Toxic Skin Eruption |
9.1% |
| International Normalised Ratio Increased |
8.2% |
| Renal Failure Acute |
6.4% |
| Vascular Purpura |
6.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
5.5% |
| Cholestasis |
4.5% |
| Renal Failure |
4.5% |
| Rhabdomyolysis |
4.5% |
| Vision Blurred |
4.5% |
| Cerebellar Syndrome |
3.6% |
| Sepsis |
3.6% |
| Somnolence |
3.6% |
| Visual Disturbance |
3.6% |
| Acute Generalised Exanthematous Pustulosis |
2.7% |
| Loss Of Consciousness |
2.7% |
| Myalgia |
2.7% |
| Neutropenia |
2.7% |
| Pain In Extremity |
2.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
34.2% |
| Product Used For Unknown Indication |
19.5% |
| Urinary Tract Infection |
4.8% |
| Sciatica |
4.5% |
| Infection |
4.0% |
| Lung Disorder |
2.9% |
| Sepsis |
2.9% |
| Prostatitis |
2.7% |
| Pyrexia |
2.5% |
| Bacteraemia |
2.3% |
| Hypertension |
2.2% |
| Lung Infection |
2.1% |
| Staphylococcal Infection |
2.1% |
| Bronchopneumopathy |
2.0% |
| Pyelonephritis |
2.0% |
| Atrial Fibrillation |
1.9% |
| Bronchitis |
1.9% |
| Ear Infection |
1.9% |
| Hiv Infection |
1.8% |
| Pneumonia |
1.7% |
|
| Thrombocytopenia |
11.7% |
| Renal Failure Acute |
9.1% |
| Cytolytic Hepatitis |
7.1% |
| Neutropenia |
6.6% |
| Toxic Skin Eruption |
6.1% |
| Renal Failure |
5.1% |
| Septic Shock |
5.1% |
| Vision Blurred |
5.1% |
| Aplastic Anaemia |
4.6% |
| Pyrexia |
4.1% |
| Stevens-johnson Syndrome |
4.1% |
| Tendonitis |
4.1% |
| Vascular Purpura |
4.1% |
| Vomiting |
4.1% |
| Gamma-glutamyltransferase Increased |
3.6% |
| Urticaria |
3.6% |
| Insomnia |
3.0% |
| Rash Morbilliform |
3.0% |
| Rhabdomyolysis |
3.0% |
| Tendon Rupture |
3.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
31.7% |
| Product Used For Unknown Indication |
18.8% |
| Hypertension |
5.3% |
| Urinary Tract Infection |
5.2% |
| Multiple Myeloma |
3.9% |
| Pyelonephritis |
3.6% |
| Bronchitis |
3.4% |
| Hiv Infection |
3.4% |
| Prophylaxis |
3.3% |
| Benign Prostatic Hyperplasia |
3.2% |
| Antibiotic Therapy |
2.2% |
| Pain |
2.2% |
| Infection Prophylaxis |
2.1% |
| Diabetes Mellitus |
1.9% |
| Diabetic Foot |
1.8% |
| Anxiety |
1.6% |
| Crohn's Disease |
1.6% |
| Lung Infection |
1.6% |
| Osteitis |
1.6% |
| Thrombosis Prophylaxis |
1.6% |
|
| Thrombocytopenia |
12.3% |
| Varicella |
12.3% |
| Renal Failure Acute |
9.7% |
| Somnolence |
7.1% |
| Toxic Skin Eruption |
7.1% |
| Cytolytic Hepatitis |
5.8% |
| Weight Decreased |
5.2% |
| Pyrexia |
4.5% |
| Henoch-schonlein Purpura |
3.9% |
| Septic Shock |
3.9% |
| Tendon Pain |
3.2% |
| Transaminases Increased |
3.2% |
| Vomiting |
3.2% |
| Acute Respiratory Failure |
2.6% |
| Cholestasis |
2.6% |
| Hypoglycaemia |
2.6% |
| Lung Disorder |
2.6% |
| Neutropenia |
2.6% |
| Rhabdomyolysis |
2.6% |
| Skin Exfoliation |
2.6% |
|
| Interacting |
| Bacterial Pyelonephritis |
15.0% |
| Lung Disorder |
15.0% |
| Pneumonia |
10.0% |
| Renal Abscess |
10.0% |
| Bronchopneumopathy |
7.5% |
| Product Used For Unknown Indication |
7.5% |
| Anticoagulant Therapy |
5.0% |
| Heart Transplant |
5.0% |
| Osteitis |
5.0% |
| Atrial Fibrillation |
2.5% |
| Deep Vein Thrombosis |
2.5% |
| Dyslipidaemia |
2.5% |
| Fungal Infection |
2.5% |
| Prophylaxis |
2.5% |
| Sepsis |
2.5% |
| Thrombosis Prophylaxis |
2.5% |
| Type 2 Diabetes Mellitus |
2.5% |
|
| Lung Disorder |
25.0% |
| International Normalised Ratio Increased |
16.7% |
| Overdose |
16.7% |
| Unevaluable Event |
16.7% |
| Gastrointestinal Haemorrhage |
8.3% |
| Prothrombin Time Shortened |
8.3% |
| Rhabdomyolysis |
8.3% |
|
